Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Single Arm, Open Label Clinical Study to Assess the Safety and Efficacy of YY-20394 in Subjects With Relapsed/Refractory Follicular Non-Hodgkin's Lymphoma

Next Previous
Trial Profile

A Phase 2, Single Arm, Open Label Clinical Study to Assess the Safety and Efficacy of YY-20394 in Subjects With Relapsed/Refractory Follicular Non-Hodgkin's Lymphoma

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Linperlisib (Primary)
  • Indications Follicular lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Shanghai Yingli Pharmaceutical

Most Recent Events

  • 12 Dec 2023 Results (n=84) of sub-group analysis assessing outcomes of linperlisib in later-line treatment of relapsed or refractory follicular lymphoma, presented at the 65th American Society of Hematology Annual Meeting and Exposition.
  • 11 Dec 2023 According to a Shanghai Yingli Pharmaceutical media release, r/r PTCL Phase 2 clinical trial enrolled 98 patients (pts) from May 2021 to October 2022 at 25 clinical sites in China.
  • 11 Dec 2023 According to a Shanghai Yingli Pharmaceutical media release, data evaluating linperlisib in relapsed or refractory peripheral T-cell lymphoma in an oral session at the American Society of Hematology 2023 Annual Meeting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top